Investor Webinar

Summary by AI BETAClose X

TheraCryf plc will host an investor webinar on April 24, 2026, at 10:00 am BST, featuring the CEO and COO to discuss progress in their lead orexin-1 receptor antagonist program for addiction, which is moving towards clinical readiness and first-in-human studies. The company is also advancing its dopamine transporter modulator program for fatigue and has a legacy oncology program. Investors can submit questions in advance via the Investor Meet Company platform.

Disclaimer*

UK 100

Latest directors dealings